TY - JOUR
T1 - Activating transcription factor-4 promotes mineralization in vascular smooth muscle cells
AU - Masuda, Masashi
AU - Miyazaki-Anzai, Shinobu
AU - Keenan, Audrey L.
AU - Shiozaki, Yuji
AU - Okamura, Kayo
AU - Chick, Wallace S.
AU - Williams, Kristina
AU - Zhao, Xiaoyun
AU - Rahman, Shaikh Mizanoor
AU - Tintut, Yin
AU - Adams, Christopher M.
AU - Miyazaki, Makoto
N1 - Funding Information:
The authors’ work was supported by grants from the NIH (R01DK096030, R01HL117062, and R01 HL132318 to M. Miyazaki). M. Masuda received a fellowship from the American Heart Association (13POST13820008).
Publisher Copyright:
© 2016 American Society for Clinical Investigation. All rights reserved.
PY - 2016/11/3
Y1 - 2016/11/3
N2 - Emerging evidence indicates that upregulation of the ER stress–induced pro-osteogenic transcription factor ATF4 plays an important role in vascular calcification, a common complication in patients with aging, diabetes, and chronic kidney disease (CKD). In this study, we demonstrated the pathophysiological role of ATF4 in vascular calcification using global Atf4 KO, smooth muscle cell–specific (SMC-specific) Atf4 KO, and transgenic (TG) mouse models. Reduced expression of ATF4 in global ATF4-haplodeficient and SMC-specific Atf4 KO mice reduced medial and atherosclerotic calcification under normal kidney and CKD conditions. In contrast, increased expression of ATF4 in SMC-specific Atf4 TG mice caused severe medial and atherosclerotic calcification. We further demonstrated that ATF4 transcriptionally upregulates the expression of type III sodium-dependent phosphate cotransporters (PiT1 and PiT2) by interacting with C/EBPβ. These results demonstrate that the ER stress effector ATF4 plays a critical role in the pathogenesis of vascular calcification through increased phosphate uptake in vascular SMCs.
AB - Emerging evidence indicates that upregulation of the ER stress–induced pro-osteogenic transcription factor ATF4 plays an important role in vascular calcification, a common complication in patients with aging, diabetes, and chronic kidney disease (CKD). In this study, we demonstrated the pathophysiological role of ATF4 in vascular calcification using global Atf4 KO, smooth muscle cell–specific (SMC-specific) Atf4 KO, and transgenic (TG) mouse models. Reduced expression of ATF4 in global ATF4-haplodeficient and SMC-specific Atf4 KO mice reduced medial and atherosclerotic calcification under normal kidney and CKD conditions. In contrast, increased expression of ATF4 in SMC-specific Atf4 TG mice caused severe medial and atherosclerotic calcification. We further demonstrated that ATF4 transcriptionally upregulates the expression of type III sodium-dependent phosphate cotransporters (PiT1 and PiT2) by interacting with C/EBPβ. These results demonstrate that the ER stress effector ATF4 plays a critical role in the pathogenesis of vascular calcification through increased phosphate uptake in vascular SMCs.
UR - http://www.scopus.com/inward/record.url?scp=85055596087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055596087&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.88646
DO - 10.1172/jci.insight.88646
M3 - Article
C2 - 27812542
AN - SCOPUS:85055596087
SN - 2379-3708
VL - 1
JO - JCI Insight
JF - JCI Insight
IS - 18
M1 - e88646
ER -